Targeting The Defective Airway Macrophage Function In Chronic Obstructive Pulmonary Disease (COPD): A New Therapeutic Approach
Funder
National Health and Medical Research Council
Funding Amount
$710,928.00
Summary
COPD/emphysema is smoking-related, incurable and a leading cause of death. New treatments are urgently needed. We have reported that airway phagocyte dysfunction and inflammation in COPD or smoke-exposed mice can be improved by novel treatments including lectins and macrolide antibiotics. We now show that these effects can be greatly improved by low-dose aspirin. We will further investigate these therapies and also novel antibiotics that have been modified to lose their anti-bacterial activity